Eglaro Tablets 15Mg (1 Box = 2 Strips) (1 Strip = 7 Tablets)

Name: Eglaro Tablets 15Mg (1 Box = 2 Strips) (1 Strip = 7 Tablets)
Brand: PHARMEVO PRIVATE LIMITED.
Price: 425.6

Brand : pharmevo private limited.

Rs. 425.60

Rs. 448.00

|

QUICK DELIVERY

Eglaro Tablets Specification

Requires Prescription (YES/NO)

Yes

Generics

Ertugliflozin

Used For

Diabetes

How it works

SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

Eglaro Tablets Usage And Safety

Dosage

Ertugliflozin

Side Effects

Female genital mycotic infections .

Drug Interactions

Insulin , insulin secretagogues .

Indication

It is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: • As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. • In addition to other medicinal products for the treatment of diabetes.

When not to Use

Hypersensitivity to ertugliflozin or any excipient in Ertugliflozin , reactions such as angioedema have occurred. Patients on dialysis.

Eglaro Tablets Precautions

Precaution

Ertugliflozin increases the risk of genital mycotic infections. Patients who have a history of genital mycotic infections or who are uncircumcised are more likely to develop genital mycotic infections. Monitor and treat appropriately .

Eglaro Tablets Warnings

Warning 1

Consider monitoring for ketoacidosis and temporarily discontinuing ertugliflozin in other clinical situations known to predispose to ketoacidosis (e.g., prolonged fasting due to acute illness or post-surgery). Ensure risk factors for ketoacidosis are resolved prior to restarting ertugliflozin.

Warning 2

Before initiating ertugliflozin, consider factors in the patient history that may predispose them to the need for amputations, such as a history of prior amputation, peripheral vascular disease, neuropathy and diabetic foot ulcers. Counsel patients about the importance of routine preventative foot care. Monitor patients receiving ertugliflozin for signs and symptoms of infection (including osteomyelitis), new pain or tenderness, sores or ulcers involving the lower limbs, and discontinue ertugliflozin if these complications occur .

Warning 3

Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. Ertugliflozin may increase the risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with ertugliflozin.

Download the Dvago App